K
Kiadis Pharma
Engaged in the clinical development and commercialization of cell-based immunotherapy products for treatment of blood cancer and blood disorders
About Kiadis Pharma
Kiadis Pharma is a biotechnology company specializing in the development of innovative cell-based immunotherapies aimed at treating life-threatening diseases, particularly cancer. The company focuses on leveraging its proprietary off-the-shelf NK (natural killer) cell platform, which utilizes NK cells from a unique universal donor to create effective treatments. Kiadis serves patients undergoing hematopoietic stem cell transplants and those battling blood cancers and solid tumors. Operating in the biopharmaceutical market, Kiadis employs a business model centered around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through partnerships, licensing agreements, and sales of approved treatments. The company's core values emphasize patient-centricity, transparency, collaboration, urgency, and quality.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1997
- Headquarters
- Amsterdam, Netherlands
- Listing
- IPO 2015
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 30.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Oncology, Patient Care, StartupAmsterdam, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 1 company, latest Apr 2019
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Kiadis Pharma.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Apr 2021 | $339M | $339M | Sanofi | ↗ |
| POST IPO EQUITY✓Other financing | Sep 2020 | $9.5M | — | US Department of War · ARMI | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Kiadis Pharma is 950 monthly website visits, down 64.8% over the last three months. Kiadis Pharma's team declined 58% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
Quest for Growth
MedSciences Capital
EQT Life Sciences
Alta Partners
Molten Ventures
Kreos Capital
US Department of War
ARMI
Other known investors2 additional known investors
Sanofi
NOM - Northern Netherlands Regional Development Agency
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kiadis Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kiadis Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.